

Tisagenlecleucel

S

Hypogammaglobulinaemia and pancytopenia: case report

A female patient developed hypogammaglobulinaemia and pancytopenia during treatment with tisagenlecleucel for refractory diffuse large B-cell lymphoma [*route, dosage, duration of treatment to reaction onset and outcome not stated*].

The female, who had refractory diffuse large B-cell lymphoma, received tisagenlecleucel on 23 March 2020. Subsequently, she developed hypogammaglobulinaemia and prolonged pancytopenia associated with tisagenlecleucel.

The female was then treated with immune-globulin, unspecified G-CSF and blood transfusions. After 8 months, she was diagnosed with COVID-19 pneumonia. She was treated with off-label IV immune globulin [IVIG]. At day-63, post symptoms onset, she was also transfused with off-label convalescent anti SARS-CoV-2 plasma [SARS-CoV-2 convalescent plasma] of 295mL. Within a week, her condition improved significantly. On day 70, she was discharged to home isolation. After 3 months of the symptoms onset, her pancytopenia resolved and at 4 months, he tested negative for SARS-CoV-2 [*not all outcomes stated*].

Bosnjak B, et al. Case Report: Convalescent Plasma Therapy Induced Anti-SARS-CoV-2 T Cell Expansion, NK Cell Maturation and Virus Clearance in a B Cell Deficient Patient After CD19 CAR T Cell Therapy. *Frontiers in Immunology* 12: Jan 2021. Available from: URL: <http://doi.org/10.3389/fimmu.2021.721738> 803608792